top of page
< Back

Muromonab CD3


Mechanism of action:

Muromonab-CD3 is an anti-CD3 murine monoclonal antibody. Muromonab-CD3 specifically binds to the CD3/TCR complex on T cells, transiently triggering the release of large amounts of cytokines such as IL-2, TNF-α, and IFN-γ, which may cause cytokine release syndrome. However, after sustained binding to CD3, muromonab-CD3 induces endocytosis of the CD3/TCR complex, promotes apoptosis due to signaling imbalance, or triggers antibody-dependent cellular phagocytosis of these T cells by macrophages. This results in a marked reduction of mature peripheral blood T cells.

Reference(s):

1. Todd PA et al. (1989). Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 


2. Wilde MI et al. (1996). Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs.

bottom of page